CoChat

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Open access
Li, Chen, Luo, Jie, Jiang, Mingyan, Wang, Keke · 2022 · Frontiers in Pharmacology
Cited by 96

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Aims: Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors play a key role in the treatment of type 2 diabetes mellitus. This meta-analysis aims to evaluate the efficacy and safety of their combination, emphatically focusing on the effects of treatment duration and add-on drugs. Methods: Seven databases were searched until June 2021 for randomized controlled trials with a duration of at least 12 weeks, evaluating the effects of combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors. Results: A total of eight eligible articles were included, pooling data retrieved from 1895 patients with type 2 diabetes mellitus. Compared to monotherapy, combination therapy resulted in a greater reduction in glycated haemoglobin (HbA1c), body weight, fasting plasma glucose (FPG), 2 h postprandial glucose (2 h PG), systolic blood pressure (SBP), body mass index (BMI) and low-density lipoprotein cholesterol (LDL-C). The decrease in HbA1c, body weight and FPG was maintained for more than 1 year, but these effects gradually regressed over time. The risk for hypoglycaemia was significantly increased with combination therapy. In addition, drug discontinuation, diarrhoea, injection-site-related events, nausea, vomiting and genital infections were more likely to occur in combination therapy. Conclusion: Glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor combination therapy showed superior effects on reducing HbA1c, body weight, FPG, 2 h PG, SBP, BMI and LDL-C, without major safety issues, when compared with monotherapy in patients with type 2 diabetes mellitus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2022.838277

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 22

  1. Ali, 2020, Combination Therapy with Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients with Type 2 Diabetes, Diabetes Care, 43, 1234, 10.2337/dc18-2460 · DOI · Paper page
  2. Brown, 2019, A Review of the Mechanism of Action, Metabolic Profile and Haemodynamic Effects of Sodium-Glucose Co-Transporter-2 Inhibitors, Diabetes Obes. Metab., 21, 9, 10.1111/dom.13650 · DOI
  3. Busch, 2017, Combination SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy: A Complementary Approach to the Treatment of Type 2 Diabetes, Postgrad. Med., 129, 686, 10.1080/00325481.2017.1342509 · DOI · Paper page
  4. Castellana, 2019, Efficacy and Safety of GLP-1 Receptor Agonists as Add-On to SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Meta-Analysis, Sci. Rep., 9, 19351, 10.1038/s41598-019-55524-w · DOI · Paper page
  5. Deol, 2017, Combination Therapy with GLP-1 Analogues and SGLT-2 Inhibitors in the Management of Diabesity: The Real World Experience, Endocrine, 55, 173, 10.1007/s12020-016-1125-0 · DOI
  6. Díaz-Trastoy, 2020, GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-World Clinical Practice, Clin. Ther., 42, e1, 10.1016/j.clinthera.2019.12.012 · DOI
  7. Doumas, 2018, Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints, Curr. Pharm. Des., 24, 1879, 10.2174/1381612824666180604113653 · DOI
  8. Ferrannini, 2015, Energy Balance after Sodium-Glucose Cotransporter 2 Inhibition, Diabetes Care, 38, 1730, 10.2337/dc15-0355 · DOI · Paper page
  9. Gorgojo-Martínez, 2017, Real-World Effectiveness and Safety of Dapagliflozin Therapy Added to a GLP1 Receptor Agonist in Patients with Type 2 Diabetes, Nutr. Metab. Cardiovasc. Dis., 27, 129, 10.1016/j.numecd.2016.11.007 · DOI
  10. Guo, 2020, The Efficacy and Safety of Combinations of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes or Obese Adults: A Systematic Review and Meta-Analysis, Endocrine, 67, 294, 10.1007/s12020-019-02175-6 · DOI
  11. Harreiter, 2021, Combined Exenatide and Dapagliflozin Has No Additive Effects on Reduction of Hepatocellular Lipids Despite Better Glycaemic Control in Patients with Type 2 Diabetes Mellitus Treated with Metformin: EXENDA, a 24-Week, Prospective, Randomized, Placebo-Controlled Pilot Trial, Diabetes Obes. Metab., 23, 1129, 10.1111/dom.14319 · DOI · Paper page
  12. Jabbour, 2018, Safety and Efficacy of Exenatide once Weekly Plus Dapagliflozin once Daily Versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial, Diabetes Care, 41, 2136, 10.2337/dc18-0680 · DOI · Paper page
  13. Jia, 2019, Standards of Medical Care for Type 2 Diabetes in China 2019, Diabetes Metab. Res. Rev., 35, e3158, 10.1002/dmrr.3158 · DOI · Paper page
  14. Kim, 2021, Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study, Diabetes Metab. J., 10.4093/dmj.2021.0232 · DOI
  15. Li, 2021, SGLT-2 Inhibitors or GLP-1 Receptor Agonists for Adults with Type 2 Diabetes: A Clinical Practice Guideline, BMJ, 373, n1091, 10.1136/bmj.n1091 · DOI · Paper page
  16. Monami, 2014, Efficacy and Safety of Sodium Glucose Co-Transport-2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials, Diabetes Obes. Metab., 16, 457, 10.1111/dom.12244 · DOI · Paper page
  17. Patoulias, 2019, Glycemic Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist on Top of Sodium-Glucose Co-Transporter-2 Inhibitor Treatment Compared to Sodium-Glucose Co-Transporter-2 Inhibitor Alone: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Diabetes Res. Clin. Pract., 158, 107927, 10.1016/j.diabres.2019.107927 · DOI
  18. Rongfeng, 2020, Efficacy of Liraglutide Combined with Dapagliflozin in the Treatment of Overweight and Obese Patients with Type Ⅱ Diabetes Mellitus and its Effects on Pancreatic Islet Function (In Chinese), China J. Mod. Med., 16, 72, 10.3969/j.issn.1005-8982.2020.16.014 · doi:10.3969/j.issn.1005-8982.2020.16.014
  19. Saroka, 2015, Sglt-2 Inhibitor Therapy Added to Glp-1 Agonist Therapy in the Management of T2dm, Endocr. Pract., 21, 1315, 10.4158/EP15877.OR · DOI
  20. Tahrani, 2016, Pharmacology and Therapeutic Implications of Current Drugs for Type 2 Diabetes Mellitus, Nat. Rev. Endocrinol., 12, 566, 10.1038/nrendo.2016.86 · DOI · Paper page
  21. Trujillo, 2017, Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes, Pharmacotherapy, 37, 927, 10.1002/phar.1962 · DOI
  22. 2016, Global Report on Diabetes

Cited by

See all 96

Metadata

Authors
Li, C., Luo, J., Jiang, M., & Wang, K.
Venue
Frontiers in Pharmacology
Published
2022-02-04
Volume
13
Pages
838277-838277
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4210635201
Cited by
96
References
23
FWCI
4.27
Type
journal article
Language
en
Open access
gold
Funders
National Natural Science Foundation of China (81703427)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.